News articles about Xencor (NASDAQ:XNCR) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Xencor earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.0579712920496 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Xencor (NASDAQ XNCR) opened at $22.67 on Tuesday. Xencor has a 52 week low of $18.55 and a 52 week high of $28.64. The stock has a market cap of $1,012.48, a P/E ratio of -22.67 and a beta of 2.09.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%. equities analysts predict that Xencor will post -1.1 EPS for the current fiscal year.
XNCR has been the subject of several recent analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. Canaccord Genuity set a $36.00 price objective on shares of Xencor and gave the stock a “buy” rating in a report on Monday, October 23rd. Zacks Investment Research raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Wednesday, November 22nd. Cantor Fitzgerald initiated coverage on shares of Xencor in a report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price objective for the company. Finally, ValuEngine lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $30.80.
In other news, major shareholder John S. Stafford III purchased 24,653 shares of Xencor stock in a transaction dated Wednesday, October 25th. The shares were bought at an average cost of $20.01 per share, with a total value of $493,306.53. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder John S. Stafford III purchased 9,215 shares of Xencor stock in a transaction dated Thursday, December 14th. The shares were purchased at an average cost of $20.76 per share, for a total transaction of $191,303.40. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 278,535 shares of company stock worth $5,526,936. Insiders own 4.14% of the company’s stock.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.